Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

PhRMA

Trump Will Sign FDA User Fee Reauthorization Bill, Ending Threat of Agency Layoffs; Industry Praises Move

Washington, DC, August 8, 2017 — Zachary Brennan reported on Endpoints News that President Donald J. Trump will sign bipartisan legislation, passed by the U.S. Senate on August 3, that reauthorize the Food and Drug Administration (FDA) user fee programs for prescription drugs, generic drugs, medical devices and biosimilars for the next five years.

A spokesman for President Trump told Focus, “The President will sign this bill, but we look forward to working with Congress to address further negotiations.”

The Senate’s passage of the House bill by a vote of 94-1 — Bernie Sanders (D-VT) was the only vote against — came more than two years after negotiations on the reauthorization began. Continue reading

PhRMA Publishes 2017 Biopharmaceutical Industry Resources; Member Companies Spent $65.5 Billion on R&D in 2016

PhRMA’s 2017 “Chart Pack”

Washington, DC, July 28, 2017 — Did you know that Pharmaceutical Research and Manufacturers of America (PhRMA) member companies invested $65.5 billion in research and development (R&D) in 2016?

Or that combined spending on brand medicines, generics and the supply chain account for 14 percent of total national health spending, with brands accounting for just half of this (7 percent)?

Or that the United States accounts for two thirds of the world’s venture capital investments in high-growth biopharmaceutical startups?

These are but a few of the facts that can be found in PhRMA’s 2017 Biopharmaceutical Research Industry Profile and the 152-page industry chart pack, Biopharmaceuticals in Perspective, which were released July 20.
Continue reading

PhRMA ‘Pipeline’ Report: 74 Percent of Medicines in Development Have Potential to Be First-in-Class Treatments

Washington, DC, July 19, 2017 — Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a new report by The Analysis Group, Inc. commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies. Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, July 18, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 28 released a new report entitled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 patients participated in clinical trials around the state in 2013, generating an estimated economic impact of $617 million.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey on June 28.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas.  The panelists were: Continue reading

PhRMA’s New ‘Let’s Talk About Cost’ Campaign Convenes National Dialogue on Medicine Costs

Washington, DC, July 17, 2017Robert Zirkelbach, Executive Vice President of Public Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), posts on the association’s blog, The Catalyst:

Discussions about costs are important. We recognize that many are struggling to access the medicine they need and have important questions about their medicine costs.  And we want to help find the answers.

We recognize that many are struggling to access the medicine they need and have important questions about their medicine costs. And we want to help find the answers.

That is why we are convening a conversation called Let’s Talk About Cost that takes a broad look at this complex issue, exploring the slowdown in medicine cost growth, the rising cost of chronic disease, insurance coverage of medicine, the role of middlemen and what our industry can do to make medicine more affordable for patients. Continue reading

Poll Respondents Appreciate Innovation’s Economic, Social Benefits And Call For More Protections

Washington, DC, July 12, 2017Mark Grayson, deputy vice president of public affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), posts on the association’s blog, The Catalyst, that, increasingly, economists and international organizations are recognizing innovation as one of the most important drivers of economic and social progress and stability.

In fact, a report released earlier this year from the Global Intellectual Property Center, declared a robust innovation environment as “essential to the success of any 21st century economy.”

However, Grayson says it’s not just think tanks and academics acknowledging the value of innovation — the public is as well.  Continue reading

Study: Mortality Rates for Elderly Have Decreased Every Year Since Creation of Medicare Part D

Washington, DC, July 11, 2017 — Nicole Longo reports that on PhRMA’s blog’s, The Catalyst’s, weekly “Medicare Monday” feature that “we’ve talked about how Medicare Part D’s competitive structure improves access to affordable prescription drug coverage for seniors and individuals with disabilities.”

“We’ve also talked about the positive impact Part D has had on America’s seniors. Today, we’re diving into how Part D has impacted mortality rates for seniors.”

In case you missed it, a recent study from the University of Illinois at Urbana-Champaign found that mortality rates for the elderly have decreased every year since the Part D program was implemented in 2006. Continue reading

New Report: More Than 50 Medicines and Vaccines in Development for HIV Infection, Treatment and Prevention

Washington, DC, June 30, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) reports that America’s biopharmaceutical companies are continuing the fight to conquer the human immunodeficiency virus (HIV), which can develop into acquired immune deficiency syndrome (AIDS).

According to a new report released on June 27 by PhRMA in partnership with The AIDS Institute, 52 medicines and vaccines are currently in development to help treat and prevent the infection.

Among the 52 medicines in development for HIV, there are 32 antiretrovirals and antivirals, 16 vaccines and four cell therapies, including a potential first-in-class medicine intended to prevent HIV from attaching to new cells and breaking through the cell membrane. Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, June 28, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) today released a new report titled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 New Jersey patients participate in clinical trials around the state, generating $617 million in economic growth.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas: Continue reading

Three PhRMA Reports Highlight Increasing Global Competition in Biopharmaceutical R&D, Posing Challenges to Future U.S. Standing

Washington, DC, June 9, 2017 — As the U.S. looks to maintain its global leadership in biopharmaceutical research and development, three new reports point to an increasingly competitive global environment — one that requires a thorough assessment of our current public policies.

That includes the biopharmaceutical industry’s investments in science, technology, engineering and mathematics (STEM)-based initiatives at the state and national levels given the growing efforts of other countries to compete for the high-wage jobs and robust economic contributions of innovative biopharmaceutical companies.

“The American biopharmaceutical industry is the global leader in research and development (R&D) and has delivered many of the treatments and cures that have saved millions of lives around the world,” said Dr. Anne Pritchett, vice president, policy and research, at the Pharmaceutical Research and Manufacturers of America (PhRMA).  Continue reading